Northwestern Medicine scientists in the laboratory of Stephen Miller, Ph.D., professor emeritus of Microbiology–Immunology, have identified the cellular and molecular mechanisms required for the ...

A vitamin A byproduct could weaken the immune system's cancer-fighting ability, according to new Princeton University ...

A vitamin A byproduct has been found to quietly disarm the immune system, allowing tumors to evade attack and weakening cancer vaccines. Scientists have now developed a drug that shuts down this ...

Dendritic cells (DCs) are central players in cancer immunity, serving as the primary link between innate and adaptive immune responses. Their functional ...

Bria-IMT demonstrates a median overall survival of 15.6 months, surpassing historical data for heavily pretreated metastatic ...

Researchers sought to determine whether zanubrutinib combined with rituximab and lenalidomide would improve remission rates in older adults with newly diagnosed DLBCL.

Cancer cells have softer membranes than healthy cells. New nanoparticles exploit this physical difference to fuse selectively with tumors and deliver mRNA therapy with minimal off-target effects.

Gemogenovatucel-T is a DNA-engineered, triple-function immunotherapy that utilizes a patient's autologous tumor cells as a source for the complete matrix of tumor-related clonal signals. Its mechanism ...

Poolbeg Pharma plc - Peer-Reviewed POLB 001 LPS Challenge Trial Paper Published in Frontiers in Immunology 28 January 2026- Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical-stage ...

Amgen Inc. ( AMGN) Q4 2025 Earnings Call February 3, 2026 4:30 PM EST ...